Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Q3 2017 Earnings Presentation
24 slides from Precigen's earnings presentation, Nov 9, 2017
Slide 1: Third Quarter 2017 Financial Results and Business Update
November 9, 2017 Third Quarter 2017 Financial Results and Business Update Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are bas
Slide 3: Business Update
Business Update Andrew Last, Ph.D. – Chief Operating Officer
Slide 4: Expanding Biotechnology's Reach and Impact
Expanding Biotechnology’s Reach and Impact Health Gene and cell therapies targeting numerous disease indications including cancer, cardiac disease, rare disorders, among others Bio-effectors for human/animal health APIs and enzymes Environment Insect control Crop protection Flowering control Food No
Slide 5: Changing the Treatment Paradigm in CAR-T Therapy
Changing the Treatment Paradigm in CAR-T Therapy CAR-T integration/delivery into patients using time-consuming and costly method CAR-T integration/delivery into patients using fast and cost effective method Apheresis Infusion of CAR-T cells into patient Viral CART Non-Viral CART Transportation of T
Slide 6: Advancing Point-of-Care CAR-T
Advancing Point-of-Care CAR-T *ASH 2016, Publication 2807 - POC CAR generated with SB and administered in <2 days against CD19+ leukemia in mouse models Advancing Point-of-Care (POC) Sleeping Beauty (SB) CAR+ mbIL15+ Switch+ T cells administered in less than 2 days into patients POC solutions will h
Slide 7: Collaborations for Non-viral CARs & TCRs
Collaborations for Non-viral CARs & TCRs CARs: Utilizing Sleeping Beauty non-viral gene integration and RTS® platform to regulate expression of mbIL15 co-expressed with CARs Two selected CAR targets are expressed on a wide range of cancers Anticipate entering clinic in 2018 TCRs: CRADA with NCI and
Slide 8: Precigen: Biotech 2.0 Platform for Human Health
Rare Diseases Precigen: Biotech 2.0 Platform for Human Health Precigen will utilize Intrexon’s world leading platform to build next-gen therapeutic products faster and cost effectively Broad pipeline of clinical and pre-clinical programs, both partnered and un-partnered Expansion of internal portfol
Slide 9: Heart Disease – High Unmet Need
Heart Disease – High Unmet Need Heart Disease is #1 cause of death in the US. 610,000 People in the US die of heart disease each year 1 in every 6 health care dollars is spent on cardiovascular disease $317 billion Health care costs and lost productivity in 2011 Xogenex* has developed a multigene ca
Slide 10: Innovative Multigene Approach to Cardiac Disease
Innovative Multigene Approach to Cardiac Disease Favorable Pre-clinical Data: Demonstrated reversal of established cardiac disease in rat model after a single pXoX treatment (** P<0.001) Mitotic marker confirmed regeneration of cardiomyocytes
Slide 11: T1D Partners – ActoBiotics Therapeutics for Type 1 Diabetes
T1D Partners – ActoBiotics® Therapeutics for Type 1 Diabetes *Takiishi et al. Diabetes (2017) 66: 448-459.Stats - http://www.diabetes.org; Market Research reports ActoBiotics® based antigen-specific immunotherapy to treat type 1 diabetes Pre-clinical animal models show remission rates of 80-90% in n
Slide 12: Clinical Development Outlook
Clinical Development Outlook Patient population # based on US only; * Estimated new cases per year; **ZIOPHARM plans to initiate pivotal trial in Q4 2017 Indication Gene/Cell Therapy Patient # Phase Recurrent Glioblastoma Ad-RTS-IL12 >10,000* Phase 3** Oral Mucositis ActoBiotics AG013 ~500,000 Phase
Slide 13: Broad Application of Innovative Arctic Solution
Broad Application of Innovative Arctic® Solution Almost half of all fruits and vegetables are wasted Unique Arctic Advantage™ solution creates benefits for commercial tree fruit varieties & vegetables across the entire supply chain – from growers to consumers – reducing food waste First target is ap
Slide 14: Commercial Launch Underway
Commercial Launch Underway US Commercial launch of fresh sliced Arctic® apples underway in Q4’2017 Non-chemical, preservative-free approach to non-browning No change to apple taste/texture Fresh sliced apple market in US estimated at ~$500 million in sales
Slide 15: Large Market Opportunity in Fruits & Vegetables
Large Market Opportunity in Fruits & Vegetables Arctic® fresh sliced apples represent Intrexon’s initial non-browning product launch into the commercial marketplace: Projected outlook for Arctic® fresh apple slices Non-browning fruits & vegetables under development at Intrexon: Cherries Pears Lettuc
Slide 16: ICP: Targeted Biological Control of Ag Pests
ICP: Targeted Biological Control of Ag Pests Intrexon Crop Protection Achieves Milestone in Development of Pioneering Self-Limiting Fall Armyworm Solution October 2017 Oxitec's Innovative Solution to Tackle Growing Diamondback Moth Pest Issue Begins Field Trials September 2017 Diamondback moth damag
Slide 17: Rising Resistance - Enormous Challenge in Crop Protection
Rising Resistance - Enormous Challenge in Crop Protection When Pesticides Run Out, Borel, 2017; EPA, Pesticides Industry Sales and Usage 2008-2012 Over $16 Billion spent annually on insecticides 10% - 16% global food production lost in major crops to insect crop damage Over $15 Billion spent annuall
Slide 18: Strong Suppression Results with Our Eco-Friendly Solution
Strong Suppression Results with Our Eco-Friendly Solution *J Econ Entomol 105: 1115-1129; J Appl Entomol 137: 1–15; PLOS ONE 10: e0126702; https://www.nimss.org/projects/view/mrp/outline/18372; ICP estimates; Harvey-Samuel et al. BMC Biology (2015) 13: 49; Ant et al. (2012) BMC Biology; Trials condu
Slide 19: Friendly Aedes – A Biopesticide for Mosquitoes
Friendly™ Aedes – A Biopesticide for Mosquitoes Regulatory designation as a biopesticide in Oct 2017 Jurisdiction transferred to Environmental Protection Agency (EPA) based on new guidance issued by the U.S. Food and Drug Administration’s Center for Veterinary Medicine Preparing to submit applicatio
Slide 20: Intrexon's Methane Bioconversion Platform (MBP)
Intrexon’s Methane Bioconversion Platform (MBP) Intrexon has developed disruptive MBP technology enabling profitable use of natural gas to produce high value industrial products via fermentation MBP has achieved six different high value chemicals with a total addressable market that exceeds $100 bil
Slide 21: 2,3 Butanediol (BDO) and Isobutanol Progress Update
2,3 Butanediol (BDO) and Isobutanol Progress Update 2,3 BDO Yield increased by 15% during Q3 reaching over 60% of first commercial scale plant target Commercial robustness of strain demonstrated with continuous production runs >400 hours Purity >99% for 2,3 BDO produced in 500 liter pilot plant Site
Slide 22: Financial Overview
Financial Overview Joel Liffmann – Senior Vice President, Finance
Slide 23: Third Quarter Financial Performance
Third Quarter Financial Performance * Non-GAAP financial measure. Select Financial Highlights 3Q 2017 3Q 2016 Revenues $46.0 M $49.0 M Collaboration and Licensing Revenues $28.1 M $30.6 M Product & Services and Other Revenues $17.9 M $18.4 M Adjusted EBITDA $(16.4) M* $(3.7) M* Impact of change in d
Slide 24: Q&A Session
INTREXON’ Q&A Session